Skip to content

The safety and efficacy of target-controlled infusion of remimazolam combined with remifentanil for aesthetic surgery anesthesia:a multicentre, single-blinded randomized controlled trial

The safety and efficacy of target-controlled infusion of remimazolam combined with remifentanil for aesthetic surgery anesthesia:a prospective, multicentre, single-blinded randomized controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095406
Enrollment
Unknown
Registered
2025-01-07
Start date
2025-01-14
Completion date
Unknown
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Remimazolam group:Remimazolam

Sponsors

Peking University International Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Aesthetic surgery patients; 2.ASA grade I to II; 3.Age 18 ~ 60 years old; 4.BMI 18~30 kg/m^2;

Exclusion criteria

Exclusion criteria: 1.Subjects refused to participate in the study; 2.Patients with sleep disorder and mental illness before enrollment; 3.Heart dysfunction, liver dysfunction, kidney dysfunction, respiratory system; 4.Dysfunction and other important organ dysfunction; 5.OSAHS and difficult airway patients; 6.Patients who are resistant to opioids and sedatives; 7.Patients with clear contraindications to the use of study protocol drugs; 8.Pregnant or lactating women and those who have a birth plan within 3 months;

Design outcomes

Primary

MeasureTime frame
Incidence of intraoperative hypoxemia in patients;

Secondary

MeasureTime frame
Heart rate;blood pressure;pulse oximetry;bispectral index;respiratory rate;prtial pressure of end tidal carbon dioxide;modified observer’s assessment of alert;

Countries

China

Contacts

Public ContactYao Lan

Peking University International Hospital

1507yaolan@sina.com+86 13671010819

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026